MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.79
-0.55
-3.37%
Closed 16:00 06/01 EDT
OPEN
16.34
PREV CLOSE
16.34
HIGH
16.34
LOW
15.05
VOLUME
199.94K
TURNOVER
--
52 WEEK HIGH
28.81
52 WEEK LOW
10.63
MARKET CAP
518.63M
P/E (TTM)
-6.5256
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRNX stock price target is 36.80 with a high estimate of 40.00 and a low estimate of 30.00.

EPS

CRNX News

More
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources
GlobeNewswire · 5d ago
H.C. Wainwright Reiterates Buy on Crinetics Pharmaceuticals, Lowers Price Target to $30
H.C. Wainwright reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and lowers the price target from $35 to $30.
Benzinga · 05/22 12:57
Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now?
Zacks · 05/14 13:51
Cantor Fitzgerald Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $38
Cantor Fitzgerald maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price target from $28 to $38.
Benzinga · 05/11 15:38
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 05/08 14:01
Crinetics Pharmaceuticals Q1 EPS $(0.710) Down From $(0.370) YoY, Sales $71.000K Down From $367.000K YoY
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.710) per share. This is a 91.89 percent decrease over losses of $(0.370) per share from the same period last year. The company reported $71.000
Benzinga · 05/08 13:07
Daily Insider Ratings Round Up 4/17/20
Seeking Alpha - Article · 04/20 12:35
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire · 04/17 21:05

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About CRNX

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
More

Webull offers kinds of Crinetics Pharmaceuticals Inc stock information, including NASDAQ:CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions.